ViewMind Announces Developer Agreement With HP to Help Revolutionise the Diagnosis and Treatment of Cognitive Disorders

• Viewmind’s Award Winning Digital Biomarkers for Cognitive Disorders Combined With HP’s Leading Edge VR Technology, Paves the Way for a Global Societal Impact in Cognitive Health

The medical device, digital health and artificial intelligence company ViewMind, announces a new development agreement with HP Inc [HPQ]. ViewMind will use HP’s new Reverb G2 Omnicept VR Headset as part of ViewMind’s medical device solution to diagnose and monitor cognitive disorders. By collaborating with HP, ViewMind can rapidly expand, scale and secure global distribution for its award-winning breakthrough technology.

ViewMind has pioneered an affordable, reliable and accessible digital biomarker for cognitive health and will draw on biosensors within the HP Reverb G2 Omnicept VR Headset to track eye movements of patients in response to visual stimulus delivered through the headset. The biometric data recorded is sent to ViewMind’s AI trained algorithms, which enable the screening, diagnosis and monitoring of cognitive disorders.

Recommended AI News: Social Media Platform Torum Announces Strategic Investment By Huobi Ventures HECO Fund

Alzheimer’s disease pathology commences around 20 years before symptoms. By the time a medical diagnosis occurs, a lot of irreversible damage has occurred.  It is therefore imperative to be able to predict accurately who will convert to Alzheimer’s and who will not convert when mild symptoms are first observed. Another area of importance is treatment impact and the ability to measure outcomes and to even screen at the very start of the disease when lifestyle changes and new drug treatments could have the greatest impact on an individual’s cognitive health longevity.

Mark Edwards, CEO ViewMind Inc, “ViewMind are delighted to be collaborating with HP to access the latest innovative HP technologies such as the new HP Reverb G2 Omnicept Edition VR Headset and to ensure ViewMind’s award-winning solution can be accessed across global markets.”

Recommended AI News: OKEx Lists Efinity’s EFI, Furthering Support for NFTS Following March Listing of Enjin

“ViewMind’s technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition. The company is well-poised for massive commercialization success, guaranteeing top-class customer satisfaction and value,” Ojaswi Rana, Best Practices Research Analyst, Frost & Sullivan.

Jay Fraser, Head of XR Developer Relations, “ViewMind choosing the HP Omnicept SDK to tackle some of the major challenges in cognitive health diagnosis  highlights HP’s commitment to solutions that can make a significant global and societal impact in digital health.”

Recommended AI News: White Label D***** Integrates RealMe Background Verification In Over 4,000 D***** Apps